Skip to main content

International Researchers Cure Horse’s Behavioral Disorders Using 4-Weeks Of CBD Treatment

A team of international researchers from Italy and Brazil published findings earlier this month in the science publication Veterinary and Animal Science in which they reported a “successful outcome of four weeks-therapy with CBD” in a clinical case involving a 22-year-old Quarter horse that was experiencing behavioral disorders.

The clinical case study was a collaboration between investigators from the Department of Veterinary Medical Sciences at the University of Bologna in Italy and the Department of Veterinary Medical Sciences at the University Metodista of São Paulo in Brazil.

At the heart of the study was a 22-year-old mare subject that was reportedly suffering from “chronic crib-biting and wind-sucking,” which are common behavioral disorders in horses for various reasons, including but not limited to poor welfare. According to the researchers, “Any alteration from the conditions found in nature can lead to the occurrence of some specific behaviours, called stereotypies which are characterised as repetitive, consistent patterns of behaviour usually defined as having no apparent ultimate or proximal functions.”

“According to the owner report, the mare had presented this behaviour for the past 15 years; previous clinical approaches, such as a cervical collar, environmental enhancement, diet change, and chemical tranquilizers (acepromazine 0,1 mg/kg T.I.D) were not successful.” the researchers stated in their findings.

“At anamnesis, it was revealed that the mare used to be a sport horse with an intensive training routine. Once her sports career was over, the owners retired her and kept her partially in the paddock and partially in the box (average 3 h/day at the paddock). The sport career was over at the age of 10 years old, while the behaviour disorder started at the age of 7 years old, getting progressively worse over the years.” the researchers stated about the horse that was the focus of the study.

“The horse was placed in therapy with commercially available isolated CBD 200 mg/ml at a dose of 0.5 mg/kg/daily q12h per os. The dose and frequency were determinate based on previous case report and veterinary pharmacological studies (Ellis and Contino 2021). During the therapy, there were no changes in food quality/quantity or the daily routine of the mare.” the researchers stated about the CBD treatment specifically.

“To assess the results of the therapy, the mare was followed up under constant observation, for 7 days before the therapy and then during the treatment by the veterinary team divided into shifts, which provided the number of hours spent with the stereotypy (Fig. 2a) pre- and during administration of CBD. The mare was also weighted weekly, with the first weight measured at the start of the 7 days observation period prior to therapy.” the researchers stated about assessing the subject’s treatment.

“The results after 30 days of therapy were positive and no regression in behaviour was seen by the owners after the treatment ended. To the best of the Authors’ knowledge, this is the first published case describing the successful treatment and management of a chronic crib-biting, wind-sucking horse with the oral administration of CBD, enhancing welfare and life quality.” the researchers concluded.

This may be the first study of its kind, however, it’s not the first animal science study in general. This latest study adds to a growing body of evidence which proves that just as cannabis can provide wellness benefits to humans, so too can it do the same for animals. Medical cannabis as it pertains to veterinary medicine is an emerging sector of the medical cannabis industry, and a particularly promising one at that.

According to Grand View Research the global veterinary medicine industry was worth an estimated $44.59 billion in 2022 alone.

Malta Home Affairs Ministry Is Reportedly ‘In Talks With A Main Bank’

A unique cannabis public policy and industry experiment is ramping up in Malta where non-profit adult-use cannabis clubs are expected in the near future. Starting next week, Malta’s government will begin accepting applications for non-profit adult-use cannabis clubs. The European nation became just the third country on earth to pass a national adult-use legalization measure in late 2021, with only Uruguay (2013) and Canada (2018) proceeding Malta. Non-profit cannabis clubs will serve as the backbone of Malta’s adult-use industry, and this week the nation’s Home Affairs Ministry reportedly entered into discussions with an unnamed ‘main bank’ that will be needed to help Malta’s emerging industry reach its full potential.

Access to the global banking system has proven to be difficult for certain entities in the public and private sector regarding cannabis commerce, although there are certainly examples of entities being able to successfully navigate the financial regulatory labyrinth in some instances. Still, getting consistent banking solutions pinned down is something that is a top priority for any emerging cannabis market, and Malta is no exception, so reports that there is progress on that front is encouraging.

A Somewhat Unique Model

Cannabis clubs are not a new phenomenon, so from afar, what is going on in Malta may not seem significant. After all, Uruguay and Canada both already permit cannabis clubs to operate in some fashion in certain jurisdictions. For that matter, Barcelona is home to hundreds of private cannabis clubs, albeit operating in a semi-grey area of the law. Yet, Malta is unique compared to those markets in that its entire cannabis commerce model will be based on licensed non-profit cannabis clubs. Home cultivation will be permitted, but the only way to legally purchase cannabis in Malta once clubs are implemented is via non-profit clubs.

It may seem nuanced, but as anyone that has paid attention to the ongoing cannabis banking saga will recognize this is a bit of a new wrinkle. Uruguay has experienced banking issues despite permitting non-profit cannabis clubs, but it also permits sales in pharmacies. That last component was the root of banking issues in Uruguay back in 2017. Major banks in Canada are the subject of a recent lawsuit due to alleged discrimination against cannabis companies. It will be interesting to see if Malta ever experiences the same hurdles given the fact that its legalization model is much more limited compared to Uruguay and Canada.

Helping Create The Blueprint

For many years I blogged about cannabis reform efforts in the United States, and many things have proven to be similar as I have transitioned to blogging about international reform efforts. Similar to different states in the U.S., within the international community there are clearly categories of nations when it comes to cannabis policy. Some are pro-cannabis, some are anti-cannabis, and some are seemingly indifferent. The pro-cannabis nations are doing what they can to get around international hurdles, and anti-cannabis nations are doing everything they can to cling to treaty provisions in an attempt to maintain the prohibition status quo wherever they can.

Due to international treaties, cannabis legalization cannot proceed unhindered in any nation. Even Uruguay and Canada had to consider international agreements and partnerships prior to legalizing, and even when they did proceed, they did so in defiance by some measures. In the Eastern Hemisphere things are proceeding differently. Leaders in nations like Malta and Germany are seeming to be getting more and more creative as they try to figure out a blueprint of sorts for what legalization may look like without violating agreements that extend beyond their borders. With that in mind, the banking discussions in Malta may not seem like a big deal, but if it can add to the previously mentioned metaphorical legalization blueprint in a meaningful way, it will indeed prove to be a very big deal.

Report Estimates Global Legal Cannabis Sales To Reach $59.6 Billion By 2027c

These are truly exciting times for the emerging international cannabis industry. After decades of prohibition policies dominating the globe, more and more countries are getting on the right side of history and legalizing medical and/or adult-use cannabis to some degree.

In addition to preventing people’s lives from being needlessly ruined, cannabis reform is helping suffering patients and ushering in a new era for an industry that has long operated in the shadows.

Legal sales will continue to increase for the foreseeable future, as reflected by a new report from cannabis data company BDSA. Below is more information about the report via a news release:

LOUISVILLE, Colo., Feb. 22, 2023 (GLOBE NEWSWIRE) — BDSA, the leading provider of market intelligence for the cannabis industry, today released its updated five-year global legal cannabis market forecast. Global legal cannabis spending grew 4.8% to $32 billion in 2022 and forecasts a compound annual growth rate (CAGR) of 13.2% from 2022 to 2027, resulting in a market size of $59.6 billion by 2027. Despite economic uncertainty and rising inflation, BDSA expects legal U.S. cannabis sales to grow 14% by the end of 2023.

“Legal cannabis spending slowed significantly in 2022 due to rapid price declines across all markets,” said Roy Bingham, Co-Founder and CEO of BDSA. “Despite this, our updated forecast predicts strong growth in the U.S. driven by developing markets, particularly the adult-use markets of Missouri, New Jersey and New York. Additionally, four of the top five U.S. markets—Florida, Illinois, Massachusetts and Michigan—will increase by a combined 9.5% in 2023, adding nearly $770 million in new spending.”

While legal cannabis sales saw rapid growth during the height of the pandemic, 2022 marked the first overall spending contractions in many mature markets throughout the U.S., with the mature adult-use markets of California, Colorado, Nevada and Oregon suffering a combined spending decline of 16.5%. While BDSA expects to see a return to growth for most mature markets in 2024, mature markets in the U.S. are expected to grow slower during the forecast period. However, several newer markets accomplished a strong expansion in 2022, and growth in new and emerging markets is expected to ramp up in the coming years. New Jersey and Montana, which launched adult-use sales in 2022, saw approximately 140% growth last year, while Missouri grew by 84% in its second full year of medical-only sales.

By 2027, adult-use sales are forecasted to contribute 78% of the total global legal cannabis spend, up from 64% in 2022. U.S. legal cannabis spending is expected to grow at a CAGR of 11.3%, from $26.1 billion in 2022 to $44.5 billion in 2027, driven primarily by the New York, Florida, New Jersey and California markets. BDSA forecasts the launch of several new adult-use markets by 2027, including Maryland and Oklahoma in 2024 and Florida and Ohio in 2025. New adult-use markets in Hawaii and Minnesota are also possible. Although BDSA does not expect any comprehensive U.S. federal regulations on cannabis in this timeframe, there is a possibility of partial reform, such as cannabis banking, within the next few years.

Globally, cannabis markets beyond the U.S. and Canada are forecast to grow at a CAGR of 40% to $9.5 billion in 2027, up from $1.8 billion in 2022. BDSA forecasts the Canadian market will see 12% overall growth this year, becoming a $5.7 billion market by 2027 at a CAGR of 6.3%. New adult-use markets and Germany and Mexico are the primary drivers of global growth, and current limited medical cannabis programs are expected to expand, primarily within the European Union and Latin America.

BDSA will cover the new market forecast report in a webinar on March 7 at 11 a.m. MT. The free webinar will explore cannabis industry growth throughout 2022, what the industry will look like by 2027, and what factors are driving growth in the U.S. and beyond. To register, visit here.

About BDSA
Headquartered in Louisville, Colorado, BDSA helps businesses improve revenues, reduce innovation risk and prioritize market expansion with accurate and actionable cannabis market intelligence, consumer research and advisory services. The company provides a holistic understanding of the cannabis market by generating insights from point-of-sale data, wholesale data, consumer research and market forecasts. To learn more, please visit bdsa.com.

Zimbabwe Tobacco Farmers Get More Incentive To Switch To Hemp

Historically, Zimbabwe has served as the top producer of tobacco on the African continent, although in recent years many tobacco farmers in Zimbabwe have transitioned to cultivating hemp due to lowering global demand for tobacco. Zimbabwe’s government more than tripled the amount of allowable THC in hemp this month, and that should further motivate farmers to switch their fields from tobacco to hemp.

Prior to this month, the legal THC threshold for hemp in Zimbabwe was .3%, which is the legal standard in most countries around the world. However, a handful of countries have already raised the threshold from .3% to 1%, and Zimbabwe has followed suit. Zimbabwe joins Australia, Ecuador, Malawi, Switzerland, and Uruguay in setting its hemp THC threshold at 1%.

Why Does It Matter?

Going from a .3% THC threshold to a 1% THC threshold may not seem like a major leap, and yet, it is very significant. Whenever a hemp crop is tested and it has a higher percentage of THC than is allowed by law, the entire crop has to be destroyed. For obvious reasons, that is a very undesirable outcome for any farmer. In Zimbabwe, where the median income is just $932, a failed crop is particularly detrimental.

By allowing farmers in Zimbabwe to cultivate hemp with a higher THC threshold, it accommodates a greater level of THC percentage variance. Farmers that were worried about their current genetics producing slightly too much THC no longer have to worry as much. They now have more cultivars to choose from when deciding what to cultivate, and the medical cannabis products that they produce will be more effective since there will be more THC involved. The cannabinoid ‘entourage effect’ will be enhanced in patients that consume said products thanks to there being more THC in them.

Limited medical cannabis was first legalized in Zimbabwe in 2018, making it only the second country on the African continent to pass such reform. Since that time several other African nations have followed in Zimbabwe’s footsteps and legalized limited medical cannabis production. Will Zimbabwe become the continental leader for hemp, just as it has served historically for tobacco? Only time will tell, but the higher THC threshold will certainly increase the odds of that happening.

Jobs, Economic Boost, And An Improved Environment

Arguably the biggest motivating factor behind Zimbabwe’s recent THC threshold change is economic stimulation. Zimbabwe is one of the poorest nations on earth, and any and all jobs that the hemp industry can create are greatly needed. Demand for hemp products, particularly CBD-based products, is strong worldwide. If Zimbabwe can produce raw hemp to be made into products, and/or produces its own finished products, it will hopefully create many career opportunities in the process.

A booming hemp industry in Zimbabwe wouldn’t just help individuals that work directly in the industry. It would also help create ancillary hemp companies, from security to storage to just about anything else that the mind can imagine. The domestic hemp industry bringing in money from afar via exports would help boost local economies, with hemp industry workers spending their wages in the areas in which they live. Everyone would benefit from an economic butterfly effect from such activity, in addition to the public benefitting directly from increased industry tax and fee revenue.

Cultivating tobacco results in degraded soil and threatened biodiversity. Tobacco farming on a large scale often involves pesticides and fertilizers that are bad for the environment. Conversely, the hemp plant requires very little inputs and actually improves the soil in which it is cultivated via a process known as soil remediation. Furthermore, roughly 4.5 trillion cigarette butts end up in our oceans, rivers, soil, and other places every year, and presumably (hopefully) that will not be the case with hemp products. With all of that in mind, any hectare in Zimbabwe that transitions from tobacco to hemp is a great thing.

A Missed Opportunity In Spain

Yesterday was a potentially big day for cannabis policy reform in Spain, however, a bill that would have set up long-needed medical and adult-use regulations failed to pass in Parliament on Tuesday. For now, the status quo remains.

As we have reported several times in recent months, Spain’s emerging cannabis industry is in desperate need of reform in order to reach its full potential. Reform would, in turn, help consumers and patients across the country.

Unfortunately, that will not happen in the immediate future, although the fight to reform Spain’s cannabis laws is far from over. Still, yesterday’s vote was indeed unfortunate, with blame being warranted towards those that voted in support of prohibition. Per Noticias Sin (translated to English):

A comprehensive legalization of cannabis, both for therapeutic and recreational use , was rejected this Tuesday in the Spanish Parliament.

The socialist party PSOE, which is part of the coalition government in Spain with the left-wing formation United We Can, was one of those who voted against it , along with part of the right-wing opposition.

His partner in the Executive supported the initiative along with other leftist forces or formations such as the liberals of Ciudadanos, in their vote in the Congress or lower house of the Spanish Parliament.

Yesterday’s vote was definitely a missed opportunity, however, cannabis advocates will never give up. Hopefully certain reasonable tweaks can be made to proposed legislation in order to get it to the finish line.

Meanwhile, the unregulated market continues to thrive in Spain. Cannabis laws may not be as bad in Spain as they are in other countries, yet even lukewarm prohibition is still prohibition, and as long as people are being harmed by Spanish prohibition there will always be a need for reform.

Lawmakers In Spain To Debate Cannabis Regulation On Tuesday

When it comes to cannabis reform efforts there are various speeds at which jurisdictions move, ranging from a rapid pace like we saw in Thailand in the last couple of years all the way to places like China where cannabis prohibition is clung to at all costs and they are seemingly somehow finding new ways to ramp up prohibition efforts.

Somewhere in between on the spectrum is Spain. As with many other things, Spain moves at its own pace when it comes to cannabis reform. Medical cannabis is legal in Spain, however, current licenses are geared towards research and exports.

Adult-use cannabis is quasi-legal in private settings in Spain, which has created a loophole of sorts that private cannabis clubs take advantage of. What Spain truly needs is domestic cannabis regulations to take away the uncertainty and help Spain’s emerging cannabis industry reach its full potential.

Fortunately, lawmakers in Spain are considering such reform, with a debate scheduled for tomorrow. The measure being considered would reportedly go beyond medical cannabis regulations. Per Infosalus (translated to English):

The Plenary of the Congress of Deputies will debate this Tuesday the Proposal for a Law of Esquerra Republicana (ERC) to regulate cannabis in an “integral” way, that is, both its therapeutic and recreational use.

One of the objectives of the Law, which ERC presented at a press conference in September 2021, is to “decriminalize” cannabis and consider it a medicine that can be accessed with a prescription.

In this way, the consumption of marijuana would be legalized in places where tobacco smoking is allowed, this would include the ability to consume cannabis outdoors and on private property.

The measure would permit for the cultivation of up to six plants within an adult residence, with a reported limit of ‘producing up to 480 grams per year.’ For context, one harvested plant cultivated using advanced techniques can yield more than 480 grams of dried cannabis flower.

Additionally, the measure would mandate that certain funds be earmarked for ‘resources to combat addiction’ and to ‘increase the awareness of the negative effects of cannabis.’ Hopefully people in Spain are already aware of the harms of prohibition, and continue to demand a more sensible approach to cannabis policy in Spain.

Study Finds That Cannabis Use Is Associated With Lower Blood Pressure Levels

A French researcher has concluded that both current and lifetime cannabis use are associated with lower blood pressure levels after assessing the relationship between cannabis use and blood pressure among a population-based cohort of over 91,000 subjects. The research findings were recently published in the journal Nature: Scientific Reports.

The investigator reported: “In adjusted covariates models, lifetime heavy cannabis use was associated with decrease in both SBP [systolic blood pressure], DBP [diastolic blood pressure], and PP [pulse pressure] in both genders, but with a higher effect among women. … Current cannabis use was associated with lower SBP levels in men and in women. Same results were observed for DBP and PP.”

He concluded, “Longitudinal studies are needed in general populations and then in hypertensive patients to highlight the potential lowered BP effect of cannabis in a medical use.”

A 2021 Israeli study of elderly hypertension subjects determined, “Cannabis treatment for three months was associated with a reduction in systolic and diastolic blood pressure, as well as heart rate.” A US study published last year in The American Journal of Medicine reported, “Current cannabis use was associated with lower resting heart rate” in middle-aged subjects. The administration of oral CBD extracts has also been associated with reduced blood pressure levels in healthy volunteers.

Numerous other studies have also demonstrated the ability of cannabinoids to influence blood pressure and other cardiovascular responses, though many of these effects are short-term in duration and subjects typically become tolerant to some of them (e.g., tachycardia). According to a literature review published in the journal Neuropharmacology: “The endocannabinergic system plays an important cardiovascular regulatory role not only in pathophysiological conditions associated with excessive hypotension but also in hypertension. Thus, the pharmacological manipulation of this system may offer novel therapeutic approaches in a variety of cardiovascular disorders.”

Full text of the study, “Association between cannabis use and blood pressure levels according to comorbidities and socioeconomic status,” appears in Nature: Scientific Reports. Additional information on cannabinoids and blood pressure regulation is available from NORML’s publicationClinical Applications for Cannabis and Cannabinoids.

Cannabis Use Prior To Bedtime Is Associated With Improved Sleep According To Israeli Study

Consuming cannabis prior to bedtime is associated with improved sleep in patients with treatment-resistant post-traumatic stress (PTS) according to data recently published in the journal Frontiers in Psychiatry.

Researchers in Israel conducted a study involving a cohort of 14 subjects with combat-related traumatic stress. All of the study’s participants previously explored various conventional treatments with those treatments proving to be unsuccessful.

According to the researchers, none of the patients were cannabis consumers prior to enrolling in the study. Study participants consumed cannabis ‘in the evenings’ in an outpatient setting for a period of at least six-months as part of the study parameters.

Investigators reported: “After treatment with cannabis, total sleep score, subjective sleep quality, and sleep duration significantly improved. … Total PTSD symptom score and its subdomains (intrusiveness, avoidance, and alertness) showed [also] improvement.” By contrast, cannabis treatment was not associated with reducing patients’ frequency of nightmares. None of the patients reported any side-effects from cannabis, nor did any elect to cease using cannabis prior to the end of the study period.

“To the best of our knowledge, this is the first published study examining long-term cannabis efficacy in chronic combat treatment-resistant PTSD patients,” authors concluded. “The study’s findings show an overall improvement in sleep quality and duration, as well as a decrease in PTSD symptoms. … Future research should clarify the long-term effects of cannabis on different groups of patients suffering from PTSD.”

Post-traumatic stress has been a qualifying condition for medical cannabis in Israel since 2014. Currently, it is estimated that roughly 10 percent of all Israelis authorized to access medical cannabis use it to treat various symptoms of PTS.

This latest study builds on prior studies, which have similarly reported improvements in sleep duration and in insomnia in patients with and without PTS. The enactment of adult-use cannabis legalization is also correlated with a decrease in the sale of over-the-counter sleep aid medications.

European Commission Refers Hungary To The Court Of Justice Over Cannabis Vote

Last week the European Commission announced that it referred Hungary to the Court of Justice of the European Union (CJEU) for voting against the European Union’s position on removing cannabis from Schedule IV of the Convention on Narcotic Drugs at a meeting back in December 2020. Below is more information about it via a news release from the European Commission:

Today, the European Commission decided to refer Hungary to the Court of Justice of the European Union for f voting against the position of the Union on the World Health Organization (WHO) recommendations on scheduling cannabis and cannabis-related substances, as outlined in the Council Decision (EU) 2021/3.

On 2 December 2020, at the reconvened 63rd session of the United Nations (UN) Commission on Narcotic Drugs, Hungary voted against the Union position twice during the vote on the WHO recommendations in the listing of the substances under international control. Under EU law, the decisions on the international scheduling of substances under the Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, and the Convention on Psychotropic Substances of 1971, fall under the exclusive competence of the European Union. Hence, the Council decision determining the Union position is binding on the EU Member States in line with the Treaty on the Functioning of the European Union.

The Commission therefore launched the infringement procedure against Hungary with a letter of formal notice sent on 18 February 2021, followed by a reasoned opinion on 12 November 2021. As the reply from the Hungarian authorities to both the letter of formal notice and reasoned opinion was unsatisfactory, the Commission has decided to refer Hungary to the Court of Justice of the European Union for failing to fulfil its obligations under the Council decision and acting in breach of the exclusive external competence of the Union as well as of the principle of sincere cooperation.

Background

On 24 January 2019, the World Health Organization presented six recommendations concerning the rescheduling of cannabis and cannabis-related substances under the UN Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, and the UN Convention on Psychotropic Substances of 1971.

On 23 November 2020, the Council adopted Council Decision (EU) 2021/3 on the position to be taken, on behalf of the European Union, at the reconvened 63rd session of the Commission on Narcotic Drugs, on the scheduling of cannabis and cannabis-related substances under the Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, and the Convention on Psychotropic Substances of 1971. The decision was addressed to the Member States in accordance with the Treaties and, according to Article 288 TFEU, was binding in its entirety for the Member States who were called upon to vote in the Commission on Narcotic Drugs.

The vote in the Commission on Narcotic Drugs concerning the WHO recommendations took place on 2 December 2020. Hungary voted against those recommendations. In addition, Hungary made a statement in the Commission on Narcotic Drugs strongly contradicting the EU position.

For More Information

Council Decision (EU) 2021/3

WHO Recommendations on cannabis and cannabis-related substances

Infringement decisions database

EU infringement procedure

Link to February 2023 infringements package